SRH Wald-Klinikum Gera GmbH Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT01900327
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

gemcitabine (gemzar) (1 trial)

Drugs in Phase 2 Trials (1)

vismodegib (erivedge) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Pancreatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2